nimesulide has been researched along with Colorectal Neoplasms in 9 studies
nimesulide: structure
nimesulide : An aromatic ether having phenyl and 2-methylsulfonamido-5-nitrophenyl as the two aryl groups.
Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of our study was to characterize the effects of two COX-2 selective inhibitors, NS-398 and nimesulide, on colorectal cancer cell proliferation, and to describe the molecular mechanisms involved." | 7.72 | Molecular mechanisms involved in the antiproliferative effect of two COX-2 inhibitors, nimesulide and NS-398, on colorectal cancer cell lines. ( Blottière, HM; Bonnet, C; Bouancheau, D; Broquet, A; Buecher, B; Denis, MG; Galmiche, JP; Heymann, MF; Jany, A, 2003) |
| "Chronic colitis was induced in mice by four cycles of administration of dextran sulfate sodium (DSS) (i." | 5.35 | Effects of nimesulide, a cyclooxygenase-2 selective inhibitor, on colitis induced tumors. ( Hirata, I; Inoue, T; Murano, M, 2008) |
| "The aim of our study was to characterize the effects of two COX-2 selective inhibitors, NS-398 and nimesulide, on colorectal cancer cell proliferation, and to describe the molecular mechanisms involved." | 3.72 | Molecular mechanisms involved in the antiproliferative effect of two COX-2 inhibitors, nimesulide and NS-398, on colorectal cancer cell lines. ( Blottière, HM; Bonnet, C; Bouancheau, D; Broquet, A; Buecher, B; Denis, MG; Galmiche, JP; Heymann, MF; Jany, A, 2003) |
| " The primary endpoints were dose-limiting toxicities (DLTs) in Cycle 1 as well as serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs) throughout the study; secondary endpoints were pharmacodynamics parameters, objective tumor response, and urinary pharmacodynamics markers of target inhibition." | 3.30 | Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors. ( Chen, YC; Dragovich, T; Jimeno, A; Kopetz, S; Kundranda, M; Lieu, C; Menter, D; Pant, S; Tchaparian, E, 2023) |
| "Chronic colitis was induced in mice by four cycles of administration of dextran sulfate sodium (DSS) (i." | 1.35 | Effects of nimesulide, a cyclooxygenase-2 selective inhibitor, on colitis induced tumors. ( Hirata, I; Inoue, T; Murano, M, 2008) |
| "Patients with ulcerative colitis (UC) exhibit an increased risk for the development of cancer of the colon and rectum." | 1.34 | Therapeutic effect of nimesulide on colorectal carcinogenesis in experimental murine ulcerative colitis. ( Abe, Y; Hirata, I; Inoue, T; Katsu, K; Maemura, K; Morita, E; Murano, M; Murano, N; Nishikawa, T; Toshina, K; Yasumoto, S, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Pant, S | 1 |
| Dragovich, T | 1 |
| Lieu, C | 1 |
| Jimeno, A | 1 |
| Kundranda, M | 1 |
| Menter, D | 1 |
| Tchaparian, E | 1 |
| Chen, YC | 1 |
| Kopetz, S | 1 |
| Jian, YS | 1 |
| Chen, CW | 1 |
| Lin, CA | 1 |
| Yu, HP | 1 |
| Lin, HY | 1 |
| Liao, MY | 1 |
| Wu, SH | 1 |
| Lin, YF | 1 |
| Lai, PS | 1 |
| Zrieki, A | 1 |
| Farinotti, R | 1 |
| Buyse, M | 1 |
| Liu, W | 1 |
| Poole, EM | 1 |
| Ulrich, CM | 1 |
| Kulmacz, RJ | 1 |
| Zhang, YJ | 1 |
| Bao, YJ | 1 |
| Dai, Q | 1 |
| Yang, WY | 1 |
| Cheng, P | 1 |
| Zhu, LM | 1 |
| Wang, BJ | 1 |
| Jiang, FH | 1 |
| Buecher, B | 1 |
| Broquet, A | 1 |
| Bouancheau, D | 1 |
| Heymann, MF | 1 |
| Jany, A | 1 |
| Denis, MG | 1 |
| Bonnet, C | 1 |
| Galmiche, JP | 1 |
| Blottière, HM | 1 |
| Escalante, RD | 1 |
| de Oliveira, EC | 1 |
| Cunha, FQ | 1 |
| Vespúcio, MV | 1 |
| Ribeiro-Silva, A | 1 |
| Aprilli, F | 1 |
| Garcia, SB | 1 |
| Inoue, T | 2 |
| Murano, M | 2 |
| Abe, Y | 1 |
| Morita, E | 1 |
| Murano, N | 1 |
| Yasumoto, S | 1 |
| Toshina, K | 1 |
| Nishikawa, T | 1 |
| Maemura, K | 1 |
| Hirata, I | 2 |
| Katsu, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 1,Two-part (Dose Escalation, Dose Expansion), Multicenter,Non-randomized,Open-label, Multiple Dose, First-in-human Study of CA102N Monotherapy and of CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors[NCT03616574] | Phase 1 | 37 participants (Actual) | Interventional | 2019-04-09 | Completed | ||
| A Phase 2, Randomized, Open Label Study to Evaluate Efficacy, Safety, and Tolerability of CA102N Combined With Trifluridine/Tipiracil (TAS-102) Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer (mCRC) Who Failed t[NCT06039202] | Phase 2 | 100 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for nimesulide and Colorectal Neoplasms
8 other studies available for nimesulide and Colorectal Neoplasms
| Article | Year |
|---|---|
Hyaluronic acid-nimesulide conjugates as anticancer drugs against CD44-overexpressing HT-29 colorectal cancer in vitro and in vivo.
Topics: Adipates; Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Colorectal N | 2017 |
Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transport | 2008 |
Polymorphic human prostaglandin H synthase-2 proteins and their interactions with cyclooxygenase substrates and inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Colorectal Neoplasms; Cyclooxygenase 2; C | 2011 |
mTOR signaling is involved in indomethacin and nimesulide suppression of colorectal cancer cell growth via a COX-2 independent pathway.
Topics: Animals; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Colorectal Neoplasms; Cycloox | 2011 |
Molecular mechanisms involved in the antiproliferative effect of two COX-2 inhibitors, nimesulide and NS-398, on colorectal cancer cell lines.
Topics: Adenocarcinoma; Apoptosis; Blotting, Western; Cell Cycle Proteins; Cell Division; Colorectal Neoplas | 2003 |
Trypanosoma cruzi infection and/or administration of the nonsteroidal anti-inflammatory nimesulide increase the number of colonic crypts overexpressing metallothioneins in rat colon carcinogenesis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carcinogens; Chagas Disease; Colorectal Neoplasms; | 2006 |
Therapeutic effect of nimesulide on colorectal carcinogenesis in experimental murine ulcerative colitis.
Topics: Animals; Colitis, Ulcerative; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Dinoprostone; Disease | 2007 |
Effects of nimesulide, a cyclooxygenase-2 selective inhibitor, on colitis induced tumors.
Topics: Administration, Oral; Analysis of Variance; Animals; Chi-Square Distribution; Chronic Disease; Colit | 2008 |